Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hwa-ping Feng

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Nature Structural Biology|June 25, 2002
Picture story. A pathogenic family businessHwa-Ping Feng
Nature Structural & Molecular Biology|August 28, 2004
Finding 'slicer'Hwa-ping Feng
Nature Structural & Molecular Biology|October 6, 2005
Crossing the species barrierHwa-ping Feng
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 12, 2018
Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infectionMakoto Kakara, Kajal Larson, Hwa-Ping Feng, et al.
Clinical Pharmacokinetics|March 20, 2015
Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactionsSauzanne Khalilieh, Hwa-Ping Feng, Ellen G J Hulskotte, et al.
Journal of Clinical Pharmacology|September 19, 2020
Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial PneumoniaZufei Zhang, Yogesh T Patel, Jill Fiedler-Kelly, et al.
European Journal of Clinical Pharmacology|July 5, 2014
Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindroneWen H Lin, Hwa-Ping Feng, Craig R Shadle, et al.
Hepatology (Baltimore, Md.)|May 12, 2012
Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteersEllen Hulskotte, Samir Gupta, Fengjuan Xuan, et al.
Antimicrobial Agents and Chemotherapy|October 31, 2018
Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid PhosphateJianying Xiao, Charles Gill, Lianzhu Liang, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2013
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancerToshihiko Doi, Kei Muro, Takayuki Yoshino, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Nature Structural Biology|June 25, 2002
Picture story. A pathogenic family businessHwa-Ping Feng
Nature Structural & Molecular Biology|August 28, 2004
Finding 'slicer'Hwa-ping Feng
Nature Structural & Molecular Biology|October 6, 2005
Crossing the species barrierHwa-ping Feng
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 12, 2018
Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infectionMakoto Kakara, Kajal Larson, Hwa-Ping Feng, et al.
Clinical Pharmacokinetics|March 20, 2015
Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactionsSauzanne Khalilieh, Hwa-Ping Feng, Ellen G J Hulskotte, et al.
Journal of Clinical Pharmacology|September 19, 2020
Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial PneumoniaZufei Zhang, Yogesh T Patel, Jill Fiedler-Kelly, et al.
European Journal of Clinical Pharmacology|July 5, 2014
Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindroneWen H Lin, Hwa-Ping Feng, Craig R Shadle, et al.
Hepatology (Baltimore, Md.)|May 12, 2012
Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteersEllen Hulskotte, Samir Gupta, Fengjuan Xuan, et al.
Antimicrobial Agents and Chemotherapy|October 31, 2018
Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid PhosphateJianying Xiao, Charles Gill, Lianzhu Liang, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2013
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancerToshihiko Doi, Kei Muro, Takayuki Yoshino, et al.
Pageof 4